Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results
November 06, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
First MANIFEST data showing signs of CPI-0610 clinical activity in JAK-inhibitor-naïve myelofibrosis patients Data showing signs of continuing activity in ruxolitinib-refractory or -intolerant...
Constellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH
October 10, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
Company will hold investor event on December 9 at 12:30 PM CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical...
Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors
October 01, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference
September 26, 2019 12:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise
September 24, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals to Participate in Two Investor Conferences
August 21, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694
August 06, 2019 08:30 ET
|
Zenith Capital Corp.
This press release is not for dissemination in the United States or through US newswire services CALGARY, Alberta, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith”) announced today...
Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
July 08, 2019 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, July 08, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company’s...
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
June 27, 2019 08:30 ET
|
Zenith Capital Corp.
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...
Constellation Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
June 13, 2019 14:57 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...